Walgreens to sell Biocon's insulin Semglee in the U.S.
Biocon Biologics targets to tap a $30 billion U.S. insulin market with two interchangeable insulins.
diabetes
November 2021
February 2020
Long-term fatigue awaits diabetics hit by Covid-19
Presence of diabetes also influences post-Covid-19 syndrome and poses challenges in recovery of patients, says a study.
Cipla: Breath of new air
Structural changes in the global pharma industry are throwing up challenges and opportunities. Enter Cipla with its expertise in medicine, and vision for relevance beyond pharma.
